User:Mr. Ibrahem/Prasugrel
Clinical data | |
---|---|
Trade names | Effient, Efient |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609027 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Platelet inhibitor (P2Y12)[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ≥79% |
Protein binding | Active metabolite: ~98% |
Elimination half-life | ~7 h (range 2 h to 15 h) |
Excretion | Urine (~68% inactive metabolites); feces (27% inactive metabolites) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C20H20FNO3S |
Molar mass | 373.44 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Prasugrel, sold under the brand name Effient and Efient, is a medication used to prevent blood clots in people with acute coronary syndrome (ACS) who getting percutaneous coronary intervention (PCI).[2] It is used together with aspirin.[2] It is taken by mouth.[2]
Common side effects include bleeding.[1] Other side effects may include thrombotic thrombocytopenic purpura and angioedema.[1] It is a platelet inhibitor of the P2Y12 platelet adenosine diphosphate (ADP)-receptor inhibitor type.[1]
Prasugrel was approved for use in Europe and the United States in 2009.[2][3] It is available as a generic medication.[4] In the United Kingdom 4 weeks of medication costs the NHS about £6 as of 2021.[4] This amount in the United States is about 30 USD.[5] It is no longer available in Canada as of 2020.[6]
References[edit]
- ^ a b c d e "DailyMed - PRASUGREL- prasugrel hydrochloride tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 30 October 2021. Retrieved 29 October 2021.
- ^ a b c d e "Efient". Archived from the original on 26 February 2021. Retrieved 29 October 2021.
- ^ "Prasugrel Monograph for Professionals". Drugs.com. Archived from the original on 27 February 2021. Retrieved 29 October 2021.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 230. ISBN 978-0857114105.
- ^ "Prasugrel Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 29 October 2021.
- ^ Lordkipanidzé, Marie; et al. (December 2020). "Implications of the Antiplatelet Therapy Gap Left with Discontinuation of Prasugrel in Canada". CJC Open. 2020. doi:10.1016/j.cjco.2020.11.021. ISSN 2589-790X.